Cite
APA Citation
Lavasani, S. M., Somlo, G., Yost, S. E., Frankel, P. H., Ruel, C., Cui, Y., Murga, M., Tang, A., Martinez, N., Kruper, L., Tumyan, L., Schmolze, D., Yeon, C., Yuan, Y., Waisman, J. R., & Mortimer, J. (2023). phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer. Cancer, 129(5), 740–749. http://access.bl.uk/ark:/81055/vdc_100177549451.0x000062